Species difference exists in the effects of 1α,25(OH)2D3 and its analogue 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 (2MD) on osteoblastic cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 112, Issue 1-3, 2008, Pages 110-116

  Li, Yan ^a   Bäckesjö, Carl Magnus ^a   Haldosén, Lars Arne ^b   Lindgren, Urban ^a  

^a Division of Orthopedics ^*  (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

1 ,25(OH)2D3; 2MD; Alkaline phosphatase (ALP); Apoptosis; Osteoblast

Indexed keywords

2 METHYLENE 19 NOR 1,25 DIHYDROXYVITAMIN D3; ALKALINE PHOSPHATASE; CALCITRIOL; CALCITRIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; RAT; SPECIES DIFFERENCE; STROMA CELL;

ALKALINE PHOSPHATASE; ANIMALS; APOPTOSIS; BONE MARROW CELLS; CALCITRIOL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; MALE; MICE; MICE, INBRED C57BL; OSTEOBLASTS; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; STROMAL CELLS;

RATTUS;

EID: 55549083476     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.09.004     Document Type: Article

References (27)

1. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., and Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner Res. 13 3 (1998) 325-349
2. Jones G., Strugnell S.A., and DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol. Rev. 78 4 (1998) 1193-1231
3. Gurlek A., and Kumar R. Regulation of osteoblast growth by interactions between transforming growth factor-beta and 1alpha,25-dihydroxyvitamin D3. Crit. Rev. Eukaryot. Gene Expr. 11 4 (2001) 299-317
4. van Driel M., Koedam M., Buurman C.J., Roelse M., Weyts F., Chiba H., Uitterlinden A.G., Pols H.A., and van Leeuwen J.P. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization. J. Cell. Biochem. 99 3 (2006) 922-935
5. 3 down-regulates expression of Phex, a marker of the mature osteoblast. Endocrinology 140 3 (1999) 1192-1199
6. Berger E., Bleiberg I., Weisman Y., Harel A., Kaye A.M., and Somjen D. Differentiation of cultured mice bone marrow into osteoblast-like cells results in acquisition of sex-specific responsiveness to gonadal steroids. J. Endocrinol. Invest. 27 7 (2004) 622-628
7. Sicinski R.R., Prahl J.M., Smith C.M., and DeLuca H.F. New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J. Med. Chem. 41 23 (1998) 4662-4674
8. Shevde N.K., Plum L.A., Clagett-Dame M., Yamamoto H., Pike J.W., and DeLuca H.F. A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. Proc. Natl. Acad. Sci. U.S.A. 99 21 (2002) 13487-13491
9. Plum L.A., Fitzpatrick L.A., Ma X., Binkley N.C., Zella J.B., Clagett-Dame M., and Deluca H.F. 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int. 17 5 (2006) 704-715
10. Rodan G.A., and Harada S. The missing bone. Cell 89 5 (1997) 677-680
11. Jilka R.L., Weinstein R.S., Bellido T., Parfitt A.M., and Manolagas S.C. Osteoblast programmed cell death (apoptosis): modulation by growth factors and cytokines. J. Bone Miner Res. 13 5 (1998) 793-802
12. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J. Clin. Invest. 104 4 (1999) 439-446
13. Suda T., Ueno Y., Fujii K., and Shinki T. Vitamin D and bone. J. Cell. Biochem. 88 2 (2003) 259-266
14. Erben R.G., Scutt A.M., Miao D., Kollenkirchen U., and Haberey M. Short-term treatment of rats with high dose 1,25-dihydroxyvitamin D3 stimulates bone formation and increases the number of osteoblast precursor cells in bone marrow. Endocrinology 138 11 (1997) 4629-4635
15. Lindgren J.U., and DeLuca H.F. Oral 1,25(OH)2D3: an effective prophylactic treatment for glucocorticoid osteopenia in rats. Calcif. Tissue Int. 35 1 (1983) 107-110
16. Lindgren J.U., Johnell O., and DeLuca H.F. Studies of bone tissue in rats treated by prednisolone and 1,25-(OH)2D3. Clin. Orthop. Relat. Res. 181 (1983) 264-268
17. Lindgren J.U., Merchant C.R., and DeLuca H.F. Effect of 1,25-dihydroxyvitamin D3 on osteopenia induced by prednisolone in adult rats. Calcif. Tissue Int. 34 3 (1982) 253-257
18. Lindgren J.U., Narechania R.G., McBeath A.A., Lange T.A., and DeLuca H.F. Effects of 1,24-dihydroxyvitamin D3 and calcitonin on fracture healing in adult rats. Clin. Orthop. Relat. Res. 160 (1981) 304-308
19. Erben R.G., Bromm S., and Stangassinger M. Therapeutic efficacy of 1alpha,25-dihydroxyvitamin D3 and calcium in osteopenic ovariectomized rats: evidence for a direct anabolic effect of 1alpha,25-dihydroxyvitamin D3 on bone. Endocrinology 139 10 (1998) 4319-4328
20. Yoshizawa T., Handa Y., Uematsu Y., Takeda S., Sekine K., Yoshihara Y., Kawakami T., Arioka K., Sato H., Uchiyama Y., Masushige S., Fukamizu A., Matsumoto T., and Kato S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet. 16 4 (1997) 391-396
21. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., and Demay M.B. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 140 11 (1999) 4982-4987
22. Tanaka H., and Seino Y. Direct action of 1,25-dihydroxyvitamin D on bone: VDRKO bone shows excessive bone formation in normal mineral condition. J. Steroid. Biochem. Mol. Biol. 89-90 1-5 (2004) 343-345
23. Lindgren J.U., DeLuca H.F., and Mazess R.B. Effects of 1,25(OH)2D3 on bone tissue in the rabbit: studies on fracture healing, disuse osteoporosis, and prednisone osteoporosis. Calcif. Tissue Int. 36 5 (1984) 591-595
24. Lian J.B., Shalhoub V., Aslam F., Frenkel B., Green J., Hamrah M., Stein G.S., and Stein J.L. Species-specific glucocorticoid and 1,25-dihydroxyvitamin D responsiveness in mouse MC3T3-E1 osteoblasts: dexamethasone inhibits osteoblast differentiation and vitamin D down-regulates osteocalcin gene expression. Endocrinology 138 5 (1997) 2117-2127
25. Tilyard M.W., Spears G.F., Thomson J., and Dovey S. Treatment of postmenopausal osteoporosis with calcitriol or calcium. N. Engl. J. Med. 326 6 (1992) 357-362
26. Morales O., Samuelsson M.K., Lindgren U., and Haldosen L.A. Effects of 1alpha,25-dihydroxyvitamin D3 and growth hormone on apoptosis and proliferation in UMR 106 osteoblast-like cells. Endocrinology 145 1 (2004) 87-94
27. Caswell A.M., Whyte M.P., and Russell R.G. Hypophosphatasia and the extracellular metabolism of inorganic pyrophosphate: clinical and laboratory aspects. Crit. Rev. Clin. Lab. Sci. 28 3 (1991) 175-232